BiotechTube

Etripamil NS 70 mg

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Supraventricular Tachycardia

Conditions

Paroxysmal Supraventricular Tachycardia

Trial Timeline

Dec 10, 2018 → Nov 13, 2020

NCT ID
NCT03635996

About Etripamil NS 70 mg

Etripamil NS 70 mg is a phase 3 stage product being developed by Medpace for Paroxysmal Supraventricular Tachycardia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03635996. Target conditions include Paroxysmal Supraventricular Tachycardia.

What happened to similar drugs?

0 of 20 similar drugs in Paroxysmal Supraventricular Tachycardia were approved

Approved (0) Terminated (3) Active (17)
🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3
🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3
🔄EculizumabAstraZenecaPhase 3
🔄DanicopanAstraZenecaPhase 3
🔄Iptacopan (LNP023)NovartisPhase 3
🔄IptacopanNovartisPhase 3
🔄LNP023 + Eculizumab + RavulizumabNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03635996Phase 3Terminated

Competing Products

20 competing products in Paroxysmal Supraventricular Tachycardia

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
44
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
36
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
44
RavulizumabAstraZenecaPre-clinical
30
EculizumabAstraZenecaPhase 3
40
DanicopanAstraZenecaPhase 3
47
LNP023NovartisPre-clinical
33
Iptacopan (LNP023)NovartisPhase 3
40
iptacopanNovartisPhase 2
35
LNP023NovartisPhase 2
35
IptacopanNovartisPre-clinical
30
IptacopanNovartisPhase 3
40
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
40
LNP023NovartisPhase 3
47
LFG316 + LNP023NovartisPhase 2
35
IptacopanNovartisPhase 3
44
CrovalimabRochePhase 3
44
ABP 959 + EculizumabAmgenPhase 3
40
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
33
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
27